By Robert Chapman — 2019
Can neurodiversity proponents keep the notion of mental pathology?
Read on www.psychologytoday.com
CLEAR ALL
The Food and Drug Administration (FDA) has approved the design of two Phase 3 clinical trials of MDMA for treating PTSD, according to the Multidisciplinary Association for Psychedelic Studies (MAPS), which is funding and leading the clinical trials.
1